Integration of network pharmacology and experimental validation to explore the pharmacological mechanism of andrographolide against asthma

Abstract

Andrographolide (AG), one of the main active components of Andrographis paniculata (Burm.f.) Wall. ex Nees, has been proved to possess the pharmacological function of anti-inflammation in multiple disease including asthma. But the potential mechanism is still not clear. In this study, network pharmacology, molecular docking and experimental validation were utilized to explore the molecular mechanism of AG in the treatment of asthma. AG-related targets and asthma-related targets were screened by Swiss Target Prediction, DrugBank, STITCH, OMIM, Genecards and TTD databases. A protein–protein interaction (PPI) network was obtained through the STRING Database. The plug-in of “Network Analyzer” in Cytoscape 3.7.1 software was used to conduct the topological analysis. GO enrichment and KEGG pathway analysis were achieved by Metascape database and Bioinformatics platform. The target-pathway network was acquired by Cytoscape 3.7.1 software. The binding affinity between AG and the target genes was evaluated by Molecular docking with AutoDockTools 1.5.6. Flow cytometry was also used to verify the mechanism behind the treatment of asthma by AG, which was predicted in network pharmacology. In total, 38 targets were identified as potential targets of AG against asthma. The top 10 targets revealed by PPI are: IL-6, IL-1B, NFKB1, MMP9, CDK2, CREBBP, MAP2K1, JAK1, AR, PRKCA. GO and KEGG analysis showed that AG treatment of asthma mainly involved protein phosphorylation, peptidyl-serine phosphorylation, peptidyl-amino acid modification and other biological processes. The main signaling pathways are Th17 cell differentiation, JAK-STAT signaling pathway and PI3K-Akt signaling pathway. Molecular docking showed that AG has higher affinity with MMP9, PRKCA, JAK2, LTGAL and LRRK2. Flow cytometry showed that Th17 cell differentiation may be the potential target of AG in the treatment of asthma. This study successfully revealed the underlying target genes and mechanism involved in the treatment of asthma for AG, providing a reference and guidance for future mechanism research.

Graphical abstract

Keywords

Asthma / Andrographolide / Network pharmacology / Molecular docking / Th17 cell differentiation / Biological Sciences / Biochemistry and Cell Biology

References

[1] CampaCC, SilvaRL, MargariaJP, PiraliT, MattosMS, KraemerLR, ReisDC, GrosaG, CopperiF, DalmarcoEM, Lima-JúniorRCP, AprileS, SalaV, BelloFD, PradoDS, Alves-FilhoJC, MedanaC, CassaliGD, TronGC, TeixeiraMM, CiraoloE, RussoRC, HirschE. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat Commun, 2018, 1: 5232.

[2] ChenS, ChenZ, DengY, ZhaS, YuL, LiD, LiangZ, YangK, LiuS, ChenR. Prevention of IL-6 signaling ameliorates toluene diisocyanate-induced steroid-resistant asthma. Allergol Int, 2022, 1: 73-82.

[3] ChenuetP, FauconnierL, MadouriF, MarchiolT, RouxelN, Ĺie LedruA, MaunyP, LoryR, UttenhoveC, van SnickJ, IwakuraY, di PadovaF, Ŕie QuesniauxV, é TogbeD, RyffelB. Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice. Clin Sci (Lond), 2017, 20: 2533-2548.

[4] EsnaultS, KellyEA, JohnsonSH, DeLainLP, HaedtMJ, NollAL, SandboN, JarjourNN. Matrix metalloproteinase-9-dependent release of IL-1 β by human eosinophils. Mediators Inflamm, 2019.

[5] Global Initiative for Asthma (2023) Global strategy for asthma management and prevention updated July 2023. www.ginasthma.org

[6] HopkinsAL. Network pharmacology: the next paradigm in drug discovery. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 11: 682-690.

[7] JieXL, LuoZR, YuJ, TongZR, LiQQ, WuJH, TaoY, FengPS, LanJP, WangP. Pi-Pa-Run-Fei-Tang alleviates lung injury by modulating IL-6/JAK2/STAT3/IL-17 and PI3K/AKT/NF-kappaB signaling pathway and balancing Th17 and Treg in murine model of OVA-induced asthma. J Ethnopharmacol, 2023, 317. 116719

[8] LiS, ZhangB. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med, 2013, 2: 110-120.

[9] Li S (1999) Possible relationship between traditional Chinese medicine ZHENG and molecular networks. The First Academic Annual Meeting of the China Association for Science and Technology

[10] LiaoW, TanWSD, WongWSF. Andrographolide restores steroid. Sensitivity to block lipopolysaccharide/IFN-γ-Induced IL-27 and airway hyperresponsiveness in mice. J Immunol, 2016, 11: 4706-4712.

[11] LuschnigP, KienzlM, RoulaD, PilicJ, AtallahR, HeinemannA, SturmEM. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochem Pharmacol, 2021, 192. 114690

[12] MenzelM, AkbarshahiH, MahmutovicI, AnderssonC, PuthiaM, UllerL. NFkappaB1 dichotomously regulates pro-inflammatory and antiviral responses in asthma. J Innate Immun, 2022, 14: 182-191.

[13] MuhammadJ, KhanA, AliA, FangL, YanjingW, XuQ, WeiD. Network pharmacology: exploring the resources and methodologies. Curr Top Med Chem, 2018, 18: 949-964.

[14] NguyenV, ZhangQ, PanF, JinQ, SunM, TangthianchaichanaJ, DuS, LuY. Zi-Su-Zi decoction improves airway hyperresponsiveness in cough-variant asthma rat model through PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1alpha/NF-kappaB signaling pathways. J Ethnopharmacol, 2023, 314. 116637

[15] NogalesC, MamdouhZM, ListM, KielC, CasasAI, SchmidtHHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci, 2022, 2: 136-150.

[16] OseiE, LeilaM, HsiehA, WarnerS, Al-FouadiM, WangM, ColeD, MaksymG, HallstrandT, TimensW, BrandsmaC, HeijinkI, HackettT. Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts: implications for asthma. Sci Rep, 2020, 10: 8721.

[17] PengS, GaoJ, LiuW, JiangC, YangX, SunY, GuoW, XuQ. Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation. Oncotarget, 2016, 49: 80262-80274.

[18] Percie du SertN, HurstV, AhluwaliaA, AlamS, AveyMT, BakerM, BrowneWJ, ClarkA, CuthillIC, DirnaglU, EmersonM, GarnerP, HolgateST, HowellsDW, KarpNA, LazicSE, LidsterK, MacCallumCJ, MacleodM, PearlEJ, PetersenOH, RawleF, ReynoldsP, RooneyK, SenaES, SilberbergSD, StecklerT, WürbelH. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol, 2020.

[19] PetersMC, McGrathKW, HawkinsGA, HastieAT, LevyBD, IsraelE, PhillipsBR, MaugerDT, ComhairSA, ErzurumSC, JohanssonMW, JarjourNN, CoverstoneAM, CastroM, HolguinF, WenzelSE, WoodruffPG, BleeckerER, FahyJV. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med, 2016, 7: 574-584.

[20] RajJP, MauryaMR, NairN, MarfatiaH, HadayeR, GogtayNJ. Efficacy and safety of AP-Bio® (KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold)—a phase III, double-blind, parallel group, randomized placebo-controlled trial. Complement Ther Med, 2023, 73. 102934

[21] RamakrishnanRK, HeialySA, HamidQ. Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev Respir Med, 2019, 11: 1057-1068.

[22] RatianiL, PachkoriaE, MamageishviliN, ShengeliaR, HovhannisyanA, PanossianA. Efficacy of Kan Jang® in patients with mild COVID-19: interim analysis of a randomized, quadruple-blind, placebo-controlled trial. Pharmaceuticals, 2022, 8: 1013.

[23] ReberLL, DaubeufF, NemskaS, FrossardN. The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma. PLoS ONE, 2012, 11. e49512

[24] SelvarajK, DeviRG, SelvarajJ, PriyaAJ. In vitro anti-inflammatory and wound healing properties of Andrographis echioides and Andrographis paniculate. Bioinformation, 2022, 18: 331-336.

[25] SulaimanI, TanK, MohtarrudinN, LimJCW, StanslasJ. Andrographolide prevented toluene diisocyanate-induced occupational asthma and aberrant airway E-cadherin distribution via p38 MAPK-dependent Nrf2 induction. Pulm Pharmacol Ther, 2018, 53: 39-51.

[26] SulaimanI, TanK, MohtarrudinN, LimJCW, StanslasJ. Andrographolide prevented toluene diisocyanate-induced occupational asthma and aberrant airway E-cadherin distribution via p38 MAPK-dependent Nrf2 induction. Pulm Pharmacol Ther, 2018, 53: 39-51.

[27] SulaimanI, OkwuofuEO, MohtarrudinN, LimJCW, StanslasJ. An Andrographis paniculata Burm Nees. extract standardized for three main Andrographolides prevents house dust mite-induced airway inflammation, remodeling, and hyperreactivity by regulating Th1/Th2 gene expression in mice. J Ethnopharmacol, 2024, 319. 117082

[28] VerstraeteK, PeelmanF, BraunH, LopezJ, RompaeyDV, DansercoerA, VandenbergheI, PauwelsK, TavernierJ, LambrechtBN, HammadH, WinterHD, BeyaertR, LippensG, SavvidesSN. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun, 2017, 8: 14937.

[29] XuC, HuangH, ZouH, ZhaoY, LiuL, ChaiR, ZhangJ. The miR-9–5p/KLF5/IL-1beta axis regulates airway smooth muscle cell proliferation and apoptosis to aggravate airway remodeling and inflammation in asthma. Biochem Genet, 2024, 62: 3996-4010.

[30] YanX, TongX, JiaY, ZhaoY, ZhangQ, HuM, LiX, LiB, MingX, XieY, WuX, YuX, QuL, XiongL, HuangF, NieJ. Baiheqingjin formula reduces inflammation in mice with asthma by inhibiting the PI3K/AKT/NF-kappab signaling pathway. J Ethnopharmacol, 2024, 321. 117565

[31] YangD, LiY, LiuT, YangL, HeL, HuangT, ZhangL, LuoJ, LiuC. IL-1β promotes IL-17A production of ILC3s to aggravate neutrophilic airway inflammation in mice. Immunology, 2023.

[32] YuQ, ShiY, ShuC, DingX, ZhuS, ShenZ, LouY. Andrographolide inhibition of Th17-regulated cytokines and JAK1/STAT3 signaling in OVA-stimulated asthma in mice. Evid-Based Complement Alternat Med, 2021.

[33] ZhuT, WuX, ZhangW, XiaoM. Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int J Mol Sci, 2015, 9: 20195-20211.

Funding

National Natural Science Foundation of China(82204873)

Zhejiang Traditional Chinese Medicine and technology program(2023ZR112)

the Research Project of Zhejiang Chinese Medical University(2022JKZKTS50)

RIGHTS & PERMISSIONS

The Author(s)